Ewing's sarcoma of soft tissues in childhood: A report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991

被引:152
作者
Raney, RB
Asmar, L
Newton, WA
Bagwell, C
Breneman, JC
Crist, W
Gehan, EA
Webber, B
Wharam, M
Wiener, ES
Anderson, JR
Maurer, HM
机构
[1] CHILDRENS CANC GRP,INTERGRP RHABDOMYOSARCOMA STUDY COMM,ARCADIA,CA
[2] PEDIAT INTERGRP STAT OFF,WASHINGTON,DC
[3] PEDIAT ONCOL GRP,CHICAGO,IL
[4] INTERGRP RHABDOMYOSARCOMA STUDY GRP,STAT OFF,OMAHA,NE
关键词
D O I
10.1200/JCO.1997.15.2.574
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: One hundred thirty of 2,792 patients (5%) registered on three Intergroup Rhabdomyosarcoma Study clinical trials (IRS-I, -II, and -III) from 1972 to 1991 had an extraosseous Ewing's sarcoma (EOE). We report here the results of multimodality therapy for this tumor. Patients and Methods: The 130 patients were less than 21 years of age; 70 (54%) were motes. Primary tumor sites were on the trunk in 41 patients, an extremity in 34, the head/neck in 23, the retroperitoneum/pelvis in 21, and other sites in 11. One hundred fourteen patients had no metastases at diagnosis. In 21 patients, the tumor was completely resected; in 30, the localized or regional tumor was grossly resected, and in 63 patients, grossly visible sarcoma was left behind. Sixteen patients (12%) had distant metastases at diagnosis. All patients were given multiagent chemotherapy and most received irradiation (XRT); none were treated with bone marrow transplantation. Results: One hundred seven patients (82%) achieved a complete response. At 10 years, 62%, 61%, and 77% of the patients were alive after treatment an IRS-I, IRS-II, or IRS-III therapeutic protocols, respectively, similar to figures obtained in all IRS patients. At last follow-up evaluation, 42 patients had died of progressive tumor and one of infection. Survival at 10 years was most likely for patients with tumor that arose in the head and neck, extremities, and trunk, and for those who underwent grossly complete tumor removal before initiation of chemotherapy. For patients with localized, gross residual tumor, adding doxorubicin (DOX) to the combination of vincristine, dactinomycin, cyclophosphamide (VAC), and XRT did not significantly improve survival in 39 patients (62% alive at 10 years) compared with that of 24 patients treated with VAC and XRT without DOX (65% alive at 10 years, P = .93). Conclusion: This series indicated that EOE in children is similar to rhabdomyosarcoma (RMS) in its response to multimodal treatment. No benefit was apparent from the addition of DOX to VAC chemotherapy in patients with gross residual EOE. (C) 1997 by American Society of Clinical Oncology.
引用
收藏
页码:574 / 582
页数:9
相关论文
共 34 条
[1]  
AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO
[2]  
2-U
[3]  
ANGERVALL L, 1975, CANCER, V36, P240, DOI 10.1002/1097-0142(197507)36:1<240::AID-CNCR2820360127>3.0.CO
[4]  
2-H
[5]  
BECROFT DMO, 1984, LANCET, V2, P400
[6]   EXTRASKELETAL EWINGS TUMOR WITH TRANSLOCATION T(11-22) IN A PATIENT WITH DOWN SYNDROME [J].
CASORZO, L ;
FESSIA, L ;
SAPINO, A ;
PONZIO, G ;
BUSSOLATI, G .
CANCER GENETICS AND CYTOGENETICS, 1989, 37 (01) :79-84
[7]   THE THIRD INTERGROUP RHABDOMYOSARCOMA STUDY [J].
CRIST, W ;
GEHAN, EA ;
RAGAB, AH ;
DICKMAN, PS ;
DONALDSON, SS ;
FRYER, C ;
HAMMOND, D ;
HAYS, DM ;
HERRMANN, J ;
HEYN, R ;
JONES, PM ;
LAWRENCE, W ;
NEWTON, W ;
ORTEGA, J ;
RANEY, RB ;
RUYMANN, FB ;
TEFFT, M ;
WEBBER, B ;
WIENER, E ;
WHARAM, M ;
VIETTI, TJ ;
MAURER, HM .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :610-630
[8]   PRIMITIVE NEUROECTODERMAL TUMOR AND EWINGS-SARCOMA [J].
DEHNER, LP .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1993, 17 (01) :1-13
[9]   EXTRAOSSEOUS EWINGS-SARCOMA VERSUS PRIMITIVE RHABDOMYOSARCOMA - DIAGNOSTIC-CRITERIA AND CLINICAL CORRELATION [J].
DICKMAN, PS ;
TRICHE, TJ .
HUMAN PATHOLOGY, 1986, 17 (09) :881-893
[10]  
Hijazi Y., 1996, Modern Pathology, V9, p7A